CA2047723A1 - Compound for improving the ovary reactions and the ova and embryo production in domestic mammals in combination with biotechnological embryo transfer - Google Patents
Compound for improving the ovary reactions and the ova and embryo production in domestic mammals in combination with biotechnological embryo transferInfo
- Publication number
- CA2047723A1 CA2047723A1 CA002047723A CA2047723A CA2047723A1 CA 2047723 A1 CA2047723 A1 CA 2047723A1 CA 002047723 A CA002047723 A CA 002047723A CA 2047723 A CA2047723 A CA 2047723A CA 2047723 A1 CA2047723 A1 CA 2047723A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- inhibin
- antibodies
- embryo
- ova
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001161 mammalian embryo Anatomy 0.000 title claims abstract description 16
- 241000124008 Mammalia Species 0.000 title claims abstract description 14
- 238000012546 transfer Methods 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 210000001672 ovary Anatomy 0.000 title claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title claims description 40
- 239000000893 inhibin Substances 0.000 claims abstract description 35
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 14
- 206010042573 Superovulation Diseases 0.000 claims abstract description 12
- 230000016087 ovulation Effects 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- 230000004071 biological effect Effects 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 238000002649 immunization Methods 0.000 claims abstract description 7
- 230000003053 immunization Effects 0.000 claims abstract description 7
- 210000002149 gonad Anatomy 0.000 claims abstract description 6
- 239000005556 hormone Substances 0.000 claims abstract description 6
- 229940088597 hormone Drugs 0.000 claims abstract description 6
- 230000005070 ripening Effects 0.000 claims abstract description 6
- 102000002746 Inhibins Human genes 0.000 claims description 28
- 108010004250 Inhibins Proteins 0.000 claims description 28
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 239000011149 active material Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 230000029849 luteinization Effects 0.000 claims description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 2
- 230000002280 anti-androgenic effect Effects 0.000 claims description 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 abstract description 22
- 241001465754 Metazoa Species 0.000 abstract description 19
- 230000001850 reproductive effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000029860 luteolysis Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940032383 estrumate Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- IFEJLMHZNQJGQU-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(Cl)=C1 IFEJLMHZNQJGQU-KXXGZHCCSA-M 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4000327A DE4000327A1 (de) | 1990-01-08 | 1990-01-08 | Arzneimittel zur verbesserung der ovarreaktion und der eizell- und embryonen- produktion bei haussaeugetieren |
| DEP4000327.2 | 1990-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2047723A1 true CA2047723A1 (en) | 1991-07-09 |
Family
ID=6397731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002047723A Abandoned CA2047723A1 (en) | 1990-01-08 | 1991-01-04 | Compound for improving the ovary reactions and the ova and embryo production in domestic mammals in combination with biotechnological embryo transfer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0463138B1 (enrdf_load_stackoverflow) |
| AU (1) | AU649994B2 (enrdf_load_stackoverflow) |
| CA (1) | CA2047723A1 (enrdf_load_stackoverflow) |
| DE (3) | DE4042408C2 (enrdf_load_stackoverflow) |
| WO (1) | WO1991010449A1 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4042408C2 (de) * | 1990-01-08 | 1995-04-06 | Stefan Heiden | Verwendung von Inhibin- neutralisierenden Antikörpern |
| JP2899534B2 (ja) * | 1994-12-09 | 1999-06-02 | 全国農業協同組合連合会 | 牛の過剰排卵誘起方法 |
| AU2022416227A1 (en) | 2021-12-15 | 2024-01-04 | Ningbo Sansheng Biological Technology Co., Ltd. | Antibody against inhibin and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341617C (en) * | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibin isolated from ovarian follicular fluid |
| AU4437485A (en) * | 1984-06-08 | 1986-01-10 | Biotechnology Australia Proprietary Limited | Inhibin isolated from ovarian follicular fluid |
| US4864019A (en) * | 1985-11-08 | 1989-09-05 | The Salk Institute For Biological Studies | Antibodies to inhibin and conjugates produced therefrom |
| EP0272309A4 (en) * | 1986-06-24 | 1989-12-19 | Salk Inst For Biological Studi | POULTRY INHIBINE. |
| US4780451B1 (en) * | 1987-01-23 | 1995-04-04 | Asua International Inc | Composition and method for producing superovulation in cattle |
| DE4042408C2 (de) * | 1990-01-08 | 1995-04-06 | Stefan Heiden | Verwendung von Inhibin- neutralisierenden Antikörpern |
-
1990
- 1990-01-08 DE DE4042408A patent/DE4042408C2/de not_active Expired - Fee Related
- 1990-01-08 DE DE4000327A patent/DE4000327A1/de active Granted
-
1991
- 1991-01-04 AU AU70552/91A patent/AU649994B2/en not_active Ceased
- 1991-01-04 CA CA002047723A patent/CA2047723A1/en not_active Abandoned
- 1991-01-04 EP EP91902160A patent/EP0463138B1/de not_active Expired - Lifetime
- 1991-01-04 DE DE59101599T patent/DE59101599D1/de not_active Expired - Fee Related
- 1991-01-04 WO PCT/EP1991/000004 patent/WO1991010449A1/de active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP0463138A1 (de) | 1992-01-02 |
| DE4000327C2 (enrdf_load_stackoverflow) | 1992-07-02 |
| EP0463138B1 (de) | 1994-05-11 |
| AU7055291A (en) | 1991-08-05 |
| DE4042408C2 (de) | 1995-04-06 |
| DE4000327A1 (de) | 1991-07-11 |
| DE59101599D1 (de) | 1994-06-16 |
| AU649994B2 (en) | 1994-06-09 |
| WO1991010449A1 (de) | 1991-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6419707B2 (ja) | 卵胞同期化後の単回リコンビナントウシｆｓｈ | |
| RU2747291C1 (ru) | Длительно действующий рекомбинантный свиной гибридный белок FSH, способ его приготовления и его применение | |
| JPS6241690B2 (enrdf_load_stackoverflow) | ||
| JPH01502669A (ja) | 精製された血小板由来の成長因子及びその精製方法 | |
| TW200846361A (en) | Expression and bioactivity of bovine follicle stimulating hormone | |
| CA2047723A1 (en) | Compound for improving the ovary reactions and the ova and embryo production in domestic mammals in combination with biotechnological embryo transfer | |
| CN115975043A (zh) | 重组促卵泡激素融合蛋白 | |
| Guico-Lamm et al. | Monoclonal antibodies specific for rat relaxin. I. Production and characterization of monoclonal antibodies that neutralize rat relaxin’s bioactivity in vivo | |
| KR890011611A (ko) | 단일클론성 항체 | |
| JP2000508293A (ja) | Ｆｓｈ作用の促進に有用な新規なペプチド | |
| US20240317845A1 (en) | Antibody against inhibin and use thereof | |
| Booman et al. | A comparative study on the use of bovine and murine monoclonal antibodies for passive immunization in cattle | |
| RU2038780C1 (ru) | Способ стимуляции репродуктивной функции коров | |
| JPS63503141A (ja) | 動物の生殖機能の調節方法 | |
| JPH01137929A (ja) | 改良された排卵処置法 | |
| JPH08154957A (ja) | 牛の過剰排卵誘起方法 | |
| WO2022241549A1 (en) | Applications of ghr-106 monoclonal antibody as a gnrh antagonist | |
| Ruginosu et al. | Searches on the application of a method of induction and syncronization of estrus in cows postpartum based on two doses of GnRH and prostaglandin F2 α, with programmed insemination | |
| Scaramuzzi et al. | THE IMPLICATIONS OF IMMUNOLOGICAL TECHNIQUES FOR THE IMPROVEMENT OF PRODUCTION EFFICIENCY IN PIGS | |
| RU2024128835A (ru) | Стимуляция суперовуляции у bos taurus | |
| GB2092156A (en) | Process for the production of human thyroid-stimulating hormone | |
| DE102007025107A1 (de) | Arzneimittel zur Behandlung von Fertilitäts- und Schwangerschaftsstörungen und immunologisch-bedingten Erkrankungen und Transplantationen zur Anwendung in der Tiermedizin, insbesondere bei Pferden sowie Verfahren zur Herstellung | |
| JPH05501858A (ja) | Ｓｒｉｆ関連ペプチドおよびそれらの使用 | |
| Counis et al. | Cell-free synthesis of rat lutropin subunits | |
| Danner | Efficacy of an equine pituitary extract to superovulate cows. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20040105 |